SCHEMBL6992466

SCHEMBL6992466

N#Cc1ccc(OC[C@@H](O)CN2CC3CN(CC4CC4)CC(C2)C32CCCC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
KMT2A Q03164 7/20 0.48
MEN1 O00255 6/20 0.48
KCNH2 Q12809 2/20 0.47
SCN1A P35498 1/20 0.47
SCN4A P35499 1/20 0.47
SCN7A Q01118 1/20 0.47
SCN5A Q14524 1/20 0.47
SCN9A Q15858 1/20 0.47
SCN2A Q99250 1/20 0.47
SCN3A Q9NY46 1/20 0.47
SCN11A Q9UI33 1/20 0.47
SCN8A Q9UQD0 1/20 0.47
SCN10A Q9Y5Y9 1/20 0.47
SIGMAR1 Q99720 1/20 0.46
AGER Q15109 1/20 0.43
ATM Q13315 1/20 0.43
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7029226 0.93 KDM4E (0.58) KDM4EALDH1A1KMT2AMEN1KCNH2
SCHEMBL6093369 0.87 KDM4E (0.56) KDM4EALDH1A1KMT2AMEN1KCNH2
SCHEMBL6093365 0.87 KDM4E (0.56) KDM4EALDH1A1KMT2AMEN1KCNH2
SCHEMBL6621017 0.84 KDM4E (0.49) KDM4EALDH1A1KMT2AMEN1KCNH2
SCHEMBL7033210 0.84 KDM4E (0.53) KDM4EALDH1A1KMT2AMEN1KCNH2
SCHEMBL2968351 0.83 KCNH2 (0.62) KDM4EALDH1A1KMT2AMEN1KCNH2
SCHEMBL5965631 0.76 KDM4E (0.58) KDM4EALDH1A1KMT2AMEN1KCNH2
SCHEMBL6993770 0.75 KDM4E (0.60) KDM4EALDH1A1KMT2AMEN1KCNH2
SCHEMBL7032087 0.75 KDM4E (0.60) KDM4EALDH1A1KMT2AMEN1KCNH2
SCHEMBL7032100 0.75 KDM4E (0.60) KDM4EALDH1A1KMT2AMEN1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2003-11-13 US disclosed
EP-1301510-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-04-16 EP disclosed
WO-2002004446-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias KCNH1, LBR, CACNA1E KDM4E 4058/4885ALDH1A1 892/4885KMT2A 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.